Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01465763 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
NCT01465763 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 614 participants.
The verdict
NCT01465763, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
Interventions
- DRUG Placebo
- DRUG tofacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01465763
The ClinicalTrials.gov registry entry for NCT01465763 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01465763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01465763 about?
NCT01465763 is a clinical study titled "A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis". This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha thera...
What is the current status of trial NCT01465763?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2012-04. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01465763?
The interventions under investigation include: Placebo (DRUG), tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01465763?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.